** Shares of Royalty Pharma gain 5.73% to $27.70 premarket
** Co says it will pay about $1.1 billion to acquire RP Management, which manages the healthcare firm's operations, to simplify its corporate structure
** RPRX buys royalties of future drugs from academic labs and biotechs
** The acquisition will generate cash savings of greater than $100 million in 2026 and greater than $175 million in 2030 and drive cumulative savings of greater than $1.6 billion over 10 years, RPRX says
** Co adds its board has also approved a new $3 billion share repurchase program
** Co intends to repurchase $2 billion of shares in 2025, subject to market conditions
** RPRX stock fell ~9% in 2024
(Reporting by Sriparna Roy in Bengaluru)
((Sriparna.Roy@thomsonreuters.com;))
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。